Medicare GLP-1 Bridge Program: Weight Management for Medicare Beneficiaries

The utilization of GLP-1 medications for weight management among U.S. adults has surged to 11%, equating to approximately 40 million individuals. This increase aligns with the launch of the Medicare GLP-1 Bridge program, initiated by the Centers for Medicare & Medicaid Services (CMS) on July 1. The program offers temporary access to specific GLP-1 medications, such as Wegovy and Zepbound KwikPen, to eligible Medicare Part D beneficiaries at a cost of $50 per month, and will be available through 2027.

Approved by the FDA for weight loss in 2021, medications like Ozempic have prompted CMS to address Medicare Part D's typical exclusion of weight-loss drugs. The Bridge program operates independently of standard coverage options, requiring participants to be at least 18 years old with a BMI of 35 or higher, or a lower BMI accompanied by conditions like high blood pressure or a history of cardiovascular issues.

While the Bridge program does not affect deductible limits or qualify for aid through programs like Extra Help, it functions outside traditional Part D parameters and offers coverage until December 2027 unless medication needs change. The rise in GLP-1 usage correlates with a decline in obesity rates, decreasing from nearly 40% in 2022 to 36.4% by 2026, with diabetes rates having stabilized. For further details, the CMS fact sheet on the Medicare GLP-1 Bridge program provides comprehensive information.